might be a run from that level to 0.70 0.80 0.90 `?`?

AVNR:
Life Sciences -- Biotechnology
BUY ON WEAKNESS; REITERATE
THESIS ON APPROVAL AND STRONG
LAUNCH AND MARKET POTENTIAL
Investment recommendation
Reiterate BUY, $9 target on conviction of near-term FDA approval,
successful commercial Q1/11 launch. We estimate approval chances for
AVNR’s AVP-923 for PBA at 75% based on extensive talks with experts
and careful analysis of safety data. We think AVNR will drive strong PBA
awareness and conduct a strong launch in Q1/11. We think 923 will see
good uptake starting H2/11. Our $9 target is based on a pNPV analysis.
Investment highlights
• We think 923 will get a broad label, be well received by MDs,
patients on Q1/11 launch. We think many ALS, MS, stroke, brain
injury, Alzheimer’s and Parkinson’s MDs/patients are eagerly
anticipating approval of a PBA drug. Experts we have spoken to see
923 as effective and safe. We estimate $350M peak US sales and
$300M peak EU sales (Fig 1).
• We do not see sales potential reduced by label warnings or a likely
arrhythmia black box warning. Based on conversations with
clinicians, we do not think 923 will be limited by QTc warnings, or
cardiac (EKG) monitoring requirements. Black box warnings are
based on serious clinical safety events, which have been absent thus
far in 923 clinical experience.
• We see meaningful 923 sales ramp in H2/11 after initial PBA
disease awareness campaigns. We think AVNR will conduct effective
PBA awareness in Q1/11, which will be followed by strong 923 sales
growth starting in Q2/11.

http://pics.newsware.com/fc.asp?key=fc_vcc23977&date=2010-10-28

yes its from 2009... maybe they are still interested

http://www.haaretz.com/print-edition/business/market-report-banks-koor-spring-skyward-1.279960

Teva Pharmaceutical Industries stock gained 0.8% on reports that it's considering the acquisition of rights to Zenvia, a chronic pain medication being developed by a company called Avanir Pharmaceuticals. Alternately, Teva might buy the whole company, lock, stock and barrel.

RPC price target from Goldman Sachs = 4$ !!

yeah :)

i think it will be green tomorrow...

hmm lets see..

sell the stocks with win and go to weekend...

you think tomorrow will it continue or will the sell into weekend?

hi what das it mean? a pincher?

8$ rpc you mean? realy?

what do you think about RPC? will it Rebound when the 1$ is reached? which price target do you have on RPC?

hi! did you think RPC will go deeper after this high levels from last week? what do you think? it^s time for a rebound or not? rebuy at 1.20 + - ?

what do you think?

stay or sell?

why out?`it seems 1.50 is a good ground to go higher..

what do you think about tomorrow? 2$ possible?

you think it will go tommorrow to 2$?

you think it will explode?

what price target you have with AEZS?

price target?

price target! 25$ LOL

New York, NY (PRWEB) March 25, 2010 -- Mega Stock Picks, a reputable internet-based free subscriber newsletter, announced today that they are initiating full coverage on pending FDA Approval of Vimovo by POZEN, Inc. (NasdaqGM: POZN). Sign up for Mega Stock Picks free subscriber newsletter at http://www.megastockpicks.com.


Megastockpicks.com alerting the best Pharma and Penny Stocks. Sign Up for the Free NewsletterWidely known for its successful stock alerts which focus mainly on pharmaceutical and undervalued penny securities, Mega Stock Picks has issued a strong buy alert for POZN with a 6 month price target of 25.00. Mega Stock Picks has given POZN its strongest buy recommendation.

Pozen, Inc (POZN) is currently one of the top performing stocks in the small-to-mid cap biotechnology industry. We believe this company is well diversified and financially sound with current collaborations with GlaxoSmithKline (NYSE: GSK), over $46 million in cash available and potentially more coming in April 2010 from a collaboration and license agreement with AstraZeneca (NYSE: AZN) for the US approval of its pending FDA approved drug, Vimovo.

Vimovo, a combination pill of naproxen (Aleve) and immediate release esomeprazole (Nexium), for arthritis patients (the addition of esomeprazole reduces the risk of stomach ulcers), is up for FDA decision on April 30th, 2010 and Mega Stock Picks believes this exciting new drug will receive a positive response.

you think its a good taktik to buy when it is over with falling?

will it go at 5-7$ ?

how about this:

We continue to be very positive on the Pozen story. The royalty payments off Vimovo and Treximet should drive the company to cash flow positive operations in 2011. The Vimovo approval also validates the pathway for Pozen’s phase III PA-325/40 product, another potential $500+ million idea. Millions of people are taking daily aspirin for cardiovascular secondary prevention, the majority without a gastro-protectant.

PA offers significantly improved GI tolerability to enteric-coated aspirin, and the potential to increase the dose to therapeutic levels that can also treat pain and may reduce the risk of pre-cancerous colon adenomas. We see Pozen fairly-valued at $15 per share

what do you mean with LOD?

how deep you think will pozn fall after turnaround?

you think it will go above 10 this day?

i see a downtrend! why you think it will go up? theres a event for xtxi?

price target for this month on xtxi ?

pozn is more worth than 10USD! wake up¨!

you think there will be a short squezze?

u see more potential then 0.01$ ?

any statements on CRTX?? Which product will be decided by the FDA?

how high you think will pozn go on monday? maybe 20$?